FibroBiologics, Inc. (FBLG) Dividend History

Company News

• FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux

  FibroBiologics, a clinical-stage biotechnology company, has demonstrated that fibroblasts administered intravenously can facilitate remyelination in an animal model of Cuprizone-induced demyelination. This finding builds on the company's previous report on remyelination in an experimental autoimmune encephalomyelitis (EAE) animal model, providing hope for the development of transformative fibroblast-based therapies for demyelinating diseases like multiple sclerosis.

  GlobeNewswire Inc.
• FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt

  FibroBiologics, a clinical-stage biotech company, has demonstrated that intravenous fibroblasts can promote remyelination in a preclinical model of multiple sclerosis. This finding suggests the potential of fibroblast-based therapies for treating demyelinating diseases.

  GlobeNewswire Inc.
• FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes

  FibroBiologics, a clinical-stage biotechnology company, has filed a patent application for a new method to improve mitochondrial function using fibroblast-based therapies. This approach could lead to new treatment options for chronic diseases caused by mitochondrial dysfunction.

  GlobeNewswire Inc.
• FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an

  FibroBiologics has filed a patent application for a method to improve mitochondrial performance in cells using fibroblasts. This novel approach has the potential to unlock new treatment options for chronic diseases caused by mitochondrial dysfunction.

  GlobeNewswire Inc.
• D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

  FibroBiologics, a clinical-stage biotechnology company, has entered into a $25 million Standby Equity Purchase Agreement with Yorkville Advisors Global. The financing will support the completion of FibroBiologics' first-in-human trial for diabetic foot ulcers and IND-enabling studies for its psoriasis program, as well as the development of its human longevity, multiple sclerosis, and cancer indications.

  GlobeNewswire Inc.